| 引用本文: | 赵艳梅,张建康,蔡兆斌,庄让笑,潘金明,刘寿荣.Akt抑制剂的临床研究进展[J].中国现代应用药学,2017,34(4):625-630. |
| ZHAO Yanmei,ZHANG Jiankang,CAI Zhaobin,ZHUANG Rangxiao,PAN Jinming,LIU Shourong.Clinical Research Progress of Akt Inhibitors[J].Chin J Mod Appl Pharm(中国现代应用药学),2017,34(4):625-630. |
|
| 摘要: |
| 随着十几个Akt小分子抑制剂先后进入临床研究，Akt已逐渐成为抗肿瘤药物研究的热门靶点。本文主要综述Akt蛋白的结构和功能，同时详细介绍一些已进入临床试验并且极具开发应用前景的小分子Akt抑制剂，如哌立福新、MK-2206、GSK2110183等，并对它们的临床前和临床研究情况进行阐述。 |
| 关键词: Akt 临床研究 哌立福新 MK-2206 GSK2110183 GSK2141795 GDC0068 AZD5363 |
| DOI：10.13748/j.cnki.issn1007-7693.2017.04.033 |
| 分类号: |
| 基金项目: |
|
| Clinical Research Progress of Akt Inhibitors |
|
ZHAO Yanmei, ZHANG Jiankang, CAI Zhaobin, ZHUANG Rangxiao, PAN Jinming, LIU Shourong
|
|
Xixi Hospital of Hangzhou, Hangzhou 310023, China
|
| Abstract: |
| With various clinical trials being conducted of more than ten small Akt inhibitors in these years, the potential of Akt as a promising anti-cancer drug target has been validated. In this review, the structure and function of Akt as well as some promising small Akt inhibitors such as Perifosine, MK-2206 and GSK2110183 are going to be introduced. Additionally, the preclinical and clinical research will be illustrated in detail. |
| Key words: protein kinase B(Akt) clinical research perifosine MK-2206 GSK2110183 GSK2141795 GDC0068 AZD5363 |
